Why the study?
ANGPTL3 is perturbed in cardiometabolic diseases with experimental effects on renal function and lipid metabolism, but had not yet been measured in patients with T2DM and diabetic nephropathy.
Are serum levels of ANGPTL3 elevated in patients with T2DM and diabetic nephropathy compared to healthy controls, and do they correlate with renal function and lipid profile?
Are serum levels of ANGPTL3 elevated in patients with T2DM and diabetic nephropathy compared to healthy controls, and do they correlate with renal function and lipid profile?
Elevated serum ANGPTL3 levels in patients with diabetic nephropathy correlate with renal dysfunction and hypertriglyceridemia, suggesting a potential role in its pathogenesis.
Answers are grounded in this paper and cite their sources.
ANGPTL3 elevation associates with DN and renal impairment; hypothesis-generating for pathogenesis and biomarker role, no practice change yet.
BACKGROUND: Type 2 diabetes mellitus (T2DM) is a highly prevalent disease that has life-threatening consequences like micro and macrovascular complication. Diabetic nephropathy (DN) is one of the common consequences of T2DM which is related to secretory factors like hepatokines. Angiopoietin-Like Protein 3 (ANGPTL3) is a hepatokine that is perturbated in cardiometabolic diseases and experimental studies showed its effect on renal functions and lipid metabolism. For the first time, ANGPTL3 was measured in patients with T2DM and DN in the present study. METHODS: Serum levels of ANGPTL3, IL-6, and TNF-α were measured in 60 healthy control, 60 T2DM patients, and 61 DN patients. RESULTS: Serum levels of ANGPTL3 increased in T2DM (252.39 ± 66.01) and DN (284.59 ± 69.27) patients compared to controls (160.22 ± 48.96), and DN patients compared with T2DM patients. Urinary albumin excretion (UAE) was higher in the DN group compared to T2DM and control groups. Moreover, serum levels of IL-6 and TNF-α were elevated in both patient groups compared to controls. Moreover, ANGPTL3 represented a positive correlation with triglycerides, creatinine, and UAE in patients with both T2DM and DN groups and showed an inverse correlation with eGFR in patients with DN. Moreover, this hepatokine had a good potential to differentiate patients from controls, especially, DN patients. CONCLUSIONS: these findings provide invivo evidence for the relation of ANGPTL3 with renal dysfunction and hypertriglyceridemia in patients with DN which is in line with experimental findings and suggested a potential role for this hepatokine in DN pathogenesis.
No takes yet. Share an insight, caveat, or question.
Azadi et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: